Amgen's granulocyte colony-stimulating factor (filgrastim) is not an orphan drug, the firm pointed out in a Sept. 23 letter to "The Pink Sheet." "In fact, the drug's approved indication [for febrile neutropenia associated with chemotherapy] precludes it from being covered by the Orphan Drug Act," Amgen said. The patient population for Neupogen is estimated by the firm to be in the 200,000-400,000 range. The letter from Amgen was in response to a reference by the National Organization for Rare Disorders to the orphan designation of Neupogen as an example of an abuse of the law ("The Pink Sheet"Sept. 2, T&G-2). . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth